/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lyell Immunopharma, Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$22.75 0.0721(7.21%) LYEL at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 21.93
Highest Today 22.5
Today’s Open 21.93
Prev. Close 20.81
52 Week High 25.20
52 Week Low 7.65
Day’s Range: Low 21.93 High 22.5
52-Week Range: Low 7.65 High 25.20
1 day return -
1 Week return -6.68
1 month return +40.64
3 month return +70.35
6 month return +64.54
1 year return +2269.4
3 year return +462.94
5 year return -
10 year return -

Institutional Holdings

ARCH VENTURE CORP 9.48

MWG Management Ltd. 5.25

Foresite Capital Management IV, LLC 4.17

Orland Properties Ltd 3.93

Decheng Capital LLC 3.10

Almitas Capital LLC 3.02

venBio Partners LLC 2.46

Vanguard Group Inc 2.30

Foresite Capital Management V, LLC 2.12

T. Rowe Price Associates, Inc. 1.59

Alphabet Inc 1.53

Vanguard Total Stock Mkt Idx Inv 1.44

Citadel Advisors Llc 1.41

T. Rowe Price Health Sciences 1.10

SC China Holding Ltd 0.79

BlackRock Inc 0.75

Geode Capital Management, LLC 0.54

RBF LLC 0.52

Woodline Partners LP 0.51

Vanguard Institutional Extnd Mkt Idx Tr 0.48

Fidelity Extended Market Index 0.26

Schwab US Small-Cap ETF™ 0.23

Johnson & Johnson 0.21

Takeda Pharmaceutical Co Ltd 0.21

iShares Biotechnology ETF 0.18

TD Health Sciences - I 0.13

SEI Tax-Managed Small/Mid Cap F (SIMT) 0.11

Bridgeway Ultra-Small Company Market 0.09

Goldman Sachs Asset Management, L.P. 0.09

Fidelity Total Market Index 0.09

Extended Equity Market Fund K 0.09

Vanguard Health Care ETF 0.09

T. Rowe Price Health Sciences Port 0.07

Fidelity Series Total Market Index 0.07

Invesco RAFI US 1500 Small-Mid ETF 0.06

Galileo - Biotech Innovation Fund S USD 0.05

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.05

JHFunds2 Health Sciences NAV 0.04

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

State Street Russell 2000 Value CIT 0.02

Market Status

Strong Buy: 0

Buy: 0

Hold: 3

Sell: 1

Strong Sell: 0

Fundamentals

Market Cap 441.55 M

PB Ratio 1.5473

PE Ratio 0.0

Enterprise Value 233.90 M

Total Assets 490.86 M

Volume 54222

Company Financials

Annual Revenue FY23:48503000 48.5M, FY22:84683000 84.7M, FY21:10650000 10.7M, FY20:7756000 7.8M, FY19:657000 0.7M

Annual Profit FY23:null 0.0M, FY22:84683000 84.7M, FY21:10650000 10.7M, FY20:7756000 7.8M, FY19:657000 0.7M

Annual Net worth FY23:-190099000 -190.1M, FY22:-4754000 -4.8M, FY21:-285501000 -285.5M, FY20:-198533000 -198.5M, FY19:-121256000 -121.3M

Quarterly Revenue Q3/2025:15000 0.0M, Q2/2025:8000 0.0M, Q1/2025:7000 0.0M, Q3/2024:34000 0.0M, Q2/2024:13000 0.0M

Quarterly Profit Q3/2025:15000 0.0M, Q2/2025:8000 0.0M, Q1/2025:7000 0.0M, Q3/2024:34000 0.0M, Q2/2024:-4888000 -4.9M

Quarterly Net worth Q3/2025:-38846000 -38.8M, Q2/2025:-42684000 -42.7M, Q1/2025:-52195000 -52.2M, Q3/2024:-44583000 -44.6M, Q2/2024:-45809000 -45.8M

Fund house & investment objective

Company Information Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 300

Industry Biotechnology

CEO Dr. Lynn Seely M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow